ES3062263T3 - Ribociclib tablet - Google Patents

Ribociclib tablet

Info

Publication number: ES3062263T3
Authority: ES; Spain
Prior art keywords: ribociclib; tablets; opadry; amb; coating
Prior art date: 2015-04-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES22203730T

Other languages

English (en)

Spanish (es)

Inventor

Bindhumadhavan Gururajan

Arnaud Grandeury

Rui Costa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-16

Filing date

2016-04-14

Publication date

2026-04-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3062263(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-04-14 Application filed by Novartis AG filed Critical Novartis AG

2026-04-09 Application granted granted Critical

2026-04-09 Publication of ES3062263T3 publication Critical patent/ES3062263T3/es

Status Active legal-status Critical Current

2036-04-14 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES22203730T 2015-04-16 2016-04-14 Ribociclib tablet Active ES3062263T3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562148240P	2015-04-16	2015-04-16

Publications (1)

Publication Number	Publication Date
ES3062263T3 true ES3062263T3 (en)	2026-04-09

Family

ID=55806565

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES22203730T Active ES3062263T3 (en)	2015-04-16	2016-04-14	Ribociclib tablet
ES16718020T Active ES2938261T3 (es)	2015-04-16	2016-04-14	Comprimido de ribociclib

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES16718020T Active ES2938261T3 (es)	2015-04-16	2016-04-14	Comprimido de ribociclib

Country Status (31)

Country	Link
US (6)	US10799506B2 (ko)
EP (3)	EP4197530B1 (ko)
JP (1)	JP2018514523A (ko)
KR (2)	KR102750931B1 (ko)
CN (2)	CN107530292B (ko)
AR (1)	AR104257A1 (ko)
AU (5)	AU2016248017A1 (ko)
BR (1)	BR112017021283A2 (ko)
CA (1)	CA2982425C (ko)
CL (1)	CL2017002593A1 (ko)
CO (1)	CO2017010510A2 (ko)
DK (2)	DK3283058T3 (ko)
EA (1)	EA201792290A1 (ko)
EC (1)	ECSP17075052A (ko)
ES (2)	ES3062263T3 (ko)
FI (2)	FI3283058T3 (ko)
HR (2)	HRP20230053T1 (ko)
HU (1)	HUE061213T2 (ko)
IL (1)	IL254818A0 (ko)
LT (1)	LT4197530T (ko)
MX (1)	MX2017013350A (ko)
PE (1)	PE20180035A1 (ko)
PH (1)	PH12017501820A1 (ko)
PL (2)	PL3283058T3 (ko)
PT (2)	PT3283058T (ko)
RS (1)	RS67697B1 (ko)
SG (1)	SG11201708084PA (ko)
SI (2)	SI3283058T1 (ko)
TN (1)	TN2017000422A1 (ko)
TW (1)	TW201642864A (ko)
WO (1)	WO2016166703A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105828822B (zh)	2013-08-14	2019-10-18	诺华股份有限公司	用于治疗癌症的组合疗法
CN107530292B (zh) *	2015-04-16	2022-11-01	诺华股份有限公司	瑞博西尼片剂
CA3048036A1 (en)	2018-07-02	2020-01-02	Apotex Inc	Crystalline form of ribociclib succinate
KR20220054347A (ko)	2019-08-26	2022-05-02	아비나스 오퍼레이션스, 인코포레이티드	에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CN118652252A (zh)	2019-12-16	2024-09-17	卢内拉生物技术有限公司	选择性cdk4/6抑制剂型癌症治疗药物
AU2020405427B2 (en)	2019-12-16	2025-01-09	Lunella Biotech, Inc.	Selective CDK4/6 inhibitor cancer therapeutics
US20230310327A1 (en) *	2020-08-03	2023-10-05	Natco Pharma Limited	Pharmaceutical compositions comprising ribociclib
MX2022015336A (es) *	2020-09-29	2023-01-11	Laboratorios Silanes S A De C V	Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.
WO2022162122A1 (en)	2021-01-29	2022-08-04	Biotx.Ai Gmbh	Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh)	2021-07-16	2024-01-12	达纳－法伯癌症研究所公司	细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI848533B (zh)	2022-01-25	2024-07-11	瑞士商諾華公司	瑞博西尼藥物組成物
CN120112291A (zh)	2022-08-31	2025-06-06	阿尔维纳斯运营股份有限公司	雌激素受体降解剂的给药方案
EP4626890A1 (en)	2022-12-01	2025-10-08	KRKA, d.d., Novo mesto	Ribociclib salts and formulations thereof
CN121358477A (zh)	2023-03-27	2026-01-16	诺华股份有限公司	使用瑞波西利与芳香化酶抑制剂组合治疗早期乳腺癌的方法
TW202602868A (zh)	2024-04-15	2026-01-16	瑞士商諾華公司	瑞波西利的藥物組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5428812A (en) *	1977-08-09	1979-03-03	Yoshitomi Pharmaceut Ind Ltd	Preparation of coated tablet
GB9414045D0 (en)	1994-07-12	1994-08-31	Berwind Pharma Service	Moisture barrier film coating composition, method, and coated form
EP0771339B1 (en) *	1994-07-12	2003-10-15	BPSI Holdings, Inc.	Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US6448323B1 (en) *	1999-07-09	2002-09-10	Bpsi Holdings, Inc.	Film coatings and film coating compositions based on polyvinyl alcohol
ES2522346T3 (es)	2008-08-22	2014-11-14	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de CDK
US8784781B2 (en) *	2009-09-24	2014-07-22	Mcneil-Ppc, Inc.	Manufacture of chewing gum product with radiofrequency
US20120115878A1 (en)	2010-11-10	2012-05-10	John Vincent Calienni	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
JP5898701B2 (ja) *	2011-02-11	2016-04-13	ウィスタラボラトリーズリミテッド	フェノチアジンジアミニウム塩およびそれらの使用
LT2872482T (lt) *	2012-07-13	2020-12-28	Oncternal Therapeutics, Inc.	Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
EP2742940B1 (en) *	2012-12-13	2017-07-26	IP Gesellschaft für Management mbH	Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
US9867825B2 (en) *	2012-12-20	2018-01-16	Novartis Ag	Pharmaceutical combination comprising binimetinib
MA38522A1 (fr) *	2013-03-21	2017-10-31	Novartis Ag	Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
EP2810644A1 (en) *	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Oral formulation for the treatment of cardiovascular diseases
CN107530292B (zh)	2015-04-16	2022-11-01	诺华股份有限公司	瑞博西尼片剂
CN109953966A (zh) *	2017-12-26	2019-07-02	天津耀辰实业发展有限公司	一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja)	2020-09-25	2023-09-20	信越化学工業株式会社	紫外線硬化型有機変性シリコーン組成物および硬化物

2016
- 2016-04-14 CN CN201680022122.8A patent/CN107530292B/zh active Active
- 2016-04-14 DK DK16718020.7T patent/DK3283058T3/da active
- 2016-04-14 SI SI201631661T patent/SI3283058T1/sl unknown
- 2016-04-14 FI FIEP16718020.7T patent/FI3283058T3/fi active
- 2016-04-14 US US15/564,534 patent/US10799506B2/en active Active
- 2016-04-14 EP EP22203730.1A patent/EP4197530B1/en active Active
- 2016-04-14 LT LTEP22203730.1T patent/LT4197530T/lt unknown
- 2016-04-14 AR ARP160101012A patent/AR104257A1/es unknown
- 2016-04-14 EA EA201792290A patent/EA201792290A1/ru unknown
- 2016-04-14 PT PT167180207T patent/PT3283058T/pt unknown
- 2016-04-14 CN CN202211237232.XA patent/CN115554257A/zh active Pending
- 2016-04-14 PE PE2017002096A patent/PE20180035A1/es unknown
- 2016-04-14 KR KR1020177029433A patent/KR102750931B1/ko active Active
- 2016-04-14 TN TNP/2017/000422A patent/TN2017000422A1/en unknown
- 2016-04-14 PL PL16718020.7T patent/PL3283058T3/pl unknown
- 2016-04-14 HU HUE16718020A patent/HUE061213T2/hu unknown
- 2016-04-14 ES ES22203730T patent/ES3062263T3/es active Active
- 2016-04-14 MX MX2017013350A patent/MX2017013350A/es unknown
- 2016-04-14 HR HRP20230053TT patent/HRP20230053T1/hr unknown
- 2016-04-14 AU AU2016248017A patent/AU2016248017A1/en not_active Abandoned
- 2016-04-14 HR HRP20260123TT patent/HRP20260123T1/hr unknown
- 2016-04-14 PT PT222037301T patent/PT4197530T/pt unknown
- 2016-04-14 ES ES16718020T patent/ES2938261T3/es active Active
- 2016-04-14 JP JP2017553915A patent/JP2018514523A/ja active Pending
- 2016-04-14 DK DK22203730.1T patent/DK4197530T3/da active
- 2016-04-14 SG SG11201708084PA patent/SG11201708084PA/en unknown
- 2016-04-14 KR KR1020257000051A patent/KR20250009572A/ko active Pending
- 2016-04-14 WO PCT/IB2016/052136 patent/WO2016166703A1/en not_active Ceased
- 2016-04-14 RS RS20260107A patent/RS67697B1/sr unknown
- 2016-04-14 EP EP16718020.7A patent/EP3283058B1/en active Active
- 2016-04-14 BR BR112017021283A patent/BR112017021283A2/pt not_active Application Discontinuation
- 2016-04-14 SI SI201631943T patent/SI4197530T1/sl unknown
- 2016-04-14 EP EP25194967.3A patent/EP4620458A3/en active Pending
- 2016-04-14 CA CA2982425A patent/CA2982425C/en active Active
- 2016-04-14 FI FIEP22203730.1T patent/FI4197530T3/fi active
- 2016-04-14 PL PL22203730.1T patent/PL4197530T3/pl unknown
- 2016-04-15 TW TW105111921A patent/TW201642864A/zh unknown
2017
- 2017-10-01 IL IL254818A patent/IL254818A0/en unknown
- 2017-10-04 PH PH12017501820A patent/PH12017501820A1/en unknown
- 2017-10-13 CL CL2017002593A patent/CL2017002593A1/es unknown
- 2017-10-13 CO CONC2017/0010510A patent/CO2017010510A2/es unknown
- 2017-11-10 EC ECIEPI201775052A patent/ECSP17075052A/es unknown
2019
- 2019-03-20 AU AU2019201929A patent/AU2019201929B2/en active Active
2020
- 2020-08-26 US US17/003,771 patent/US20200390771A1/en not_active Abandoned
- 2020-10-06 AU AU2020250190A patent/AU2020250190A1/en not_active Abandoned
2022
- 2022-06-08 US US17/805,956 patent/US12064434B2/en active Active
- 2022-08-08 AU AU2022215155A patent/AU2022215155B2/en active Active
2024
- 2024-02-27 US US18/588,259 patent/US20250090531A1/en active Pending
- 2024-10-31 AU AU2024227794A patent/AU2024227794A1/en active Pending
- 2024-12-11 US US18/977,210 patent/US20250134893A1/en active Pending
- 2024-12-11 US US18/977,228 patent/US12419894B2/en active Active

Also Published As

Publication number	Publication date
LT4197530T (lt)	2026-02-25
PT3283058T (pt)	2023-02-03
CA2982425C (en)	2023-10-31
AU2020250190A1 (en)	2020-11-05
EP3283058A1 (en)	2018-02-21
HRP20230053T1 (hr)	2023-03-03
US20250134893A1 (en)	2025-05-01
PH12017501820A1 (en)	2018-04-23
EP4620458A2 (en)	2025-09-24
CA2982425A1 (en)	2016-10-20
AU2024227794A1 (en)	2024-11-21
TW201642864A (zh)	2016-12-16
PE20180035A1 (es)	2018-01-09
IL254818A0 (en)	2017-12-31
KR20250009572A (ko)	2025-01-17
AU2016248017A1 (en)	2017-10-19
CL2017002593A1 (es)	2018-05-18
US10799506B2 (en)	2020-10-13
HUE061213T2 (hu)	2023-05-28
EP3283058B1 (en)	2022-11-16
SI3283058T1 (sl)	2023-03-31
PT4197530T (pt)	2026-02-05
CN115554257A (zh)	2023-01-03
BR112017021283A2 (pt)	2018-06-26
US20200390771A1 (en)	2020-12-17
WO2016166703A1 (en)	2016-10-20
CN107530292A (zh)	2018-01-02
FI4197530T3 (fi)	2026-02-03
US20250090531A1 (en)	2025-03-20
SI4197530T1 (sl)	2026-03-31
US20250127785A1 (en)	2025-04-24
KR20170137101A (ko)	2017-12-12
AR104257A1 (es)	2017-07-05
SG11201708084PA (en)	2017-10-30
KR102750931B1 (ko)	2025-01-09
PL3283058T3 (pl)	2023-03-20
ES2938261T3 (es)	2023-04-05
AU2022215155B2 (en)	2024-08-01
MX2017013350A (es)	2018-01-25
AU2022215155A1 (en)	2022-09-01
AU2019201929B2 (en)	2020-07-09
FI3283058T3 (fi)	2023-03-01
AU2019201929A1 (en)	2019-04-11
HRP20260123T1 (hr)	2026-03-13
EP4197530A1 (en)	2023-06-21
EP4620458A3 (en)	2025-10-22
EP4197530B1 (en)	2025-11-12
US12064434B2 (en)	2024-08-20
CO2017010510A2 (es)	2018-03-20
US12419894B2 (en)	2025-09-23
US20180071292A1 (en)	2018-03-15
ECSP17075052A (es)	2018-02-28
US20230104792A1 (en)	2023-04-06
TN2017000422A1 (en)	2019-01-16
DK3283058T3 (da)	2023-02-13
JP2018514523A (ja)	2018-06-07
PL4197530T3 (pl)	2026-03-23
RS67697B1 (sr)	2026-02-27
CN107530292B (zh)	2022-11-01
EA201792290A1 (ru)	2018-02-28
DK4197530T3 (da)	2026-02-09

Publication	Publication Date	Title
ES3062263T3 (en)	2026-04-09	Ribociclib tablet
US12186316B2 (en)	2025-01-07	Pharmaceutical compositions
US20060251723A1 (en)	2006-11-09	Formulations of a SRC/ABL inhibitor
JP2019526591A (ja)	2019-09-19	ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法
CN105407925A (zh)	2016-03-16	用于泡腾剂型的制造工艺
HK40089304A (en)	2023-10-13	Ribociclib tablet
HK1243319A1 (en)	2018-07-13	Ribociclib tablet
HK1243319B (en)	2023-02-03	Ribociclib tablet
EA042324B1 (ru)	2023-02-03	Таблетка, содержащая рибоциклиб
JP6283314B2 (ja)	2018-02-21	アナグリプチン含有固形製剤
NZ768247B2 (en)	2024-09-03	Method for treating cancer